COSTA MESA, Calif./IReach–PRNewswire/–WCCT Global™, an international specialized clinical research organization, will be presenting results from an asthma clinical trial conducted at their facilities at the upcoming 15th Annual Congress of International Drug Discovery Science & Technology in Osaka, Japan.

The conference, themed “Dedicated to Accelerating Drug Innovation,” will take place from July 25-27, 2017. WCCT will be presenting on the asthma clinical trial entitled “Pharmacokinetics, Safety, and Tolerability of a New Fluticasone Propionate Multidose Dry Powder Inhaler Compared with Fluticasone Propionate Diskus in Healthy Adults.” The study, which took place in 2012, was recently published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery.

The asthma clinical trial was conducted at WCCT’s large, Phase I clinical pharmacology unit in Cypress, CA. The study was a single-center, open-label, randomized, three-period crossover, single-dose pilot study in healthy Japanese and matched Caucasian subjects. In addition to asthma clinical research, WCCT Global owns one of the top-performing sites for conducting ethnobridging clinical studies, specifically in Japanese subjects. The study enrolled 30 (15 Caucasian, 15 Japanese) healthy male and female subjects aged 20 to 45 years; with Caucasian and Japanese subjects matched 1:1 with respect to gender, age, and height.

This asthma clinical trial demonstrated that systemic exposure to inhaled single doses of Fluticasone propionate (an inhaled corticosteroid with well-established safety and efficacy profiles) was comparable between healthy adult Japanese and Caucasian subjects for each dose and inhaler evaluated.

WCCT’s Medical Director, and Principal Investigator for this study, Dr. Apinya Vutikullird, commented: “It was an honor and privilege to work on this great ethnobridging clinical research study with the new Fluticasone Propionate Multidose Dry Powder Inhaler that is crucial to the treatment of persistent asthma. The dedication to providing innovative and effective therapies is dear to WCCT Global, myself, and all those who will be attending this world-renowned conference which focuses on the most exciting innovation and advancements in the industry.”

While WCCT conducts research in various therapeutic areas, the company was founded upon asthma clinical research and plans to continue contributing to the development of new and innovative treatments for this condition in the future.